Syntermed's Emory Toolbox and NeuroQ have Expanding Global Footprint in Asia

Share Article

Emory Toolbox 4.0 with Syntermed IDS™ and SmartReport™ now offer physicians an arsenal of smarter, diagnostic heart imaging tools. The versatility and adaptability of Emory Toolbox and NeuroQ is gaining momentum in various Asian markets including Taiwan, China and Korea.

The globalization of Emory Toolbox and NeuroQ into the Asian market, specifically Taiwan, China and Korea has gained momentum. -- Michael Lee, CEO, Syntermed, Inc.

Earlier this month, Syntermed's Emory Toolbox was demonstrated at the 15th annual Chinese Nuclear Imaging Conference through sponsorship by Lado Beijing, a new Asian market distribution partner and Syntermed. During the scientific sessions, Guang-Uei Hung, MD, Chinese nuclear cardiologist at Chang Bing Show Chwan Memorial Hospital, Taiwan, China, presented data about the Taiwan experience with myocardial perfusion SPECT and referenced the role of Emory Toolbox software.

Key findings from Dr. Hung's Taiwan study reports quantitative SPECT (MPS) using the Emory Toolbox software (including SyncTool™ for LV Dyssynchrony) provides a comprehensive assessment of cardiac perfusion. "MPI has a prognostic value as a gatekeeper of invasive coronary intervention," says Hung. "The useful information from MPI facilitates the management of treatment planning for CAD." He concluded that SPECT MPI with Tl-201 demonstrated diagnostic results that are as good as Tc-99m tracers. Dr. Hung continues to collaborate with Ji Chen, PhD, Emory University, a nuclear cardiology researcher who developed, with his colleagues at Emory University, expanded functionality of the Emory Toolbox, specifically SyncTool™, a quantitative diagnostic tool used in phase analysis of LV dyssynchrony for congestive heart failure. (1)    

(1)G Hung. Diagnosing CAD: additional markers from myocardial perfusion SPECT.(online)The Journal of Biomedical Research, 2013 27(6):467-477.

"The globalization of Emory Toolbox and NeuroQ into the Asian market, specifically Taiwan, China and Korea has gained momentum," says Michael Lee, CEO, Syntermed, Inc. "Syntermed's new agreements with Lado Beijing, Shanghai United Imaging, and Korea Computer Motion ISG continue to demonstrate the versatility and adaptability of Emory Toolbox and NeuroQ for all types of nuclear platforms. For example, In South America, Emory Toolbox is currently being utilized in a clinical study sponsored by IAEA to evaluate the diagnosis of heart failure in a population at high-risk for Chagas Disease.”

Emory Toolbox 4.0 with Syntermed IDS™ and SmartReport™ now offer physicians an arsenal of smarter, diagnostic heart imaging tools. "Here in the U.S., we are seeing the adoption of clinical decision support powered by Syntermed IDS as a bridge to EMR integration opportunities between the radiology/nuclear cardiology lab and the hospital enterprise system," add Lee.

SyncTool is a phase analysis software tool that analyzes the benefits of cardiac resynchronization therapy (CRT) in heart failure patients. It has been proven to be more sensitive than TDI Echo to analyze LV Dyssynchrony. SyncTool analysis takes just seconds and uses the same data from perfusion studies. The reporting process can also be applied to any Gated SPECT MPI data set or previously stored image, and provides prognostic information from the 3D perfusion images about the presence and location of scar tissue. In addition to myocardial perfusion SPECT and PET studies, SyncTool can also be used with FDG-PET studies for patients with ischemic cardiomyopathy.

About Syntermed, Inc.: an Atlanta-based imaging and informatics company supporting SPECT and PET imaging for heart and brain studies with quantification and decision support software.

Syntermed signature products: Emory Toolbox, now in its fourth generation, is utilized by nuclear cardiology labs worldwide; SyncTool™ for advanced phase analysis imaging studies of left ventricle dyssynchrony; NeuroQ for PET-FDG brain imaging, and now NeuroQ SPECT brain imaging software, used in the differential diagnosis of dementia.

A full snapshot of the Syntermed products can be found at RSNA digital profile website
Michael Lee, CEO, and Ken Van Train, President will be available at the
RSNA meeting, Syntermed Booth 7711 (North Hall B) to provide additional details
about Syntermed's pipeline products and market expansion.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Roberts
Visit website